Sugi Predict

Sugi Predict / Compounds / SCHEMBL20834979

SCHEMBL20834979

SCHEMBL20834979

[N-]=[N+]=NCCCNC(=O)C[C@H](N)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OTC P00480 1/20 0.44
▸ DDAH1 O94760 3/20 0.36
▸ SLC1A3 P43003 2/20 0.34
▸ SLC1A2 P43004 2/20 0.34
▸ SLC1A1 P43005 2/20 0.34
▸ GRIK1 P39086 3/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ NOS2 P35228 2/20 0.33
▸ GRIK2 Q13002 2/20 0.33
▸ GRM1 Q13255 1/20 0.33
▸ GRM2 Q14416 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15473014 0.90 OTC (0.40) OTCDDAH1SLC1A3SLC1A2SLC1A1
SCHEMBL15483719 0.80 OTC (0.50) OTCDDAH1CYP2C19NOS2NOD1
SCHEMBL18557536 0.79 TP53 (0.50) MEN1KMT2A
SCHEMBL15618211 0.79 OTC (0.49) OTCDDAH1CYP2C19NOS2NOD1
SCHEMBL29878793 0.78 DPP7 (0.38) NOS1
SCHEMBL15618245 0.78 OTC (0.51) OTCDDAH1CYP2C19NOS2NOD1
SCHEMBL20528882 0.77 OTC (0.57) OTCDDAH1CYP2C19NOS2NOD1
SCHEMBL1768892 0.76 GSR (0.48) OTCSLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL1768889 0.76 GSR (0.48) OTCSLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL23568449 0.76 CA2 (0.36) OTCCA2CA9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210340586-A1 Methods of Producing Full-Length Antibodies Using E. coli SUTRO BIOPHARMA, INC. 2021-11-04 — — US disclosed
US-10596270-B2 Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates SUTRO BIOPHARMA, INC. (US) 2020-03-24 — — US disclosed
US-20190083641-A1 ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES SUTRO BIOPHARMA, INC. 2019-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340586-A1 Methods of Producing Full-Length Antibodies Using E. coli MRPL21, TXNRD1, PRDX3 OTC 2651/4885DDAH1 1819/4885SLC1A3 2465/4885
US-10596270-B2 Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates FOLR1, FOLR2, DHFR OTC 2474/4885DDAH1 1045/4885SLC1A3 632/4885
US-20190083641-A1 ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES FOLR1, FOLR2, DHFR OTC 2474/4885DDAH1 1045/4885SLC1A3 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback